percutaneous transluminal angioplasty and stenting (PTAS)	medical-management group	The probability of the occurrence of a primary end-point event	2624	2877	he probability of the occurrence of a primary end-point event over time differed significantly between the two treatment groups (P = 0.009), with 1-year rates of the primary end point of 20.0% in the PTAS group and 12.2% in the medical-management group.
percutaneous transluminal angioplasty and stenting (PTAS)	medical-management group	risk of death and stroke	11683	11833	Treatment with the Wingspan stent system for patients with intracranial stenosis carries substantial risk of death and stroke and should be abandoned.
percutaneous transluminal angioplasty and stenting (PTAS)	medical-management group	The probability of the occurrence of a primary end-point event	2623	2877	The probability of the occurrence of a primary end-point event over time differed significantly between the two treatment groups (P = 0.009), with 1-year rates of the primary end point of 20.0% in the PTAS group and 12.2% in the medical-management group.
percutaneous transluminal angioplasty and stenting (PTAS)	medical-management group	risk of death and stroke	2321	2537	The 30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002)
percutaneous transluminal angioplasty and stenting (PTAS)	medical-management group	The 30-day rate of stroke or death	2321	2538	The 30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).
